Proteomic Analysis in Type 2 Diabetes Patients before and after a Very Low Calorie Diet Reveals Potential Disease State and Intervention Specific Biomarkers by Sleddering, M.A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/138935
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
RESEARCH ARTICLE
Proteomic Analysis in Type 2 Diabetes
Patients before and after a Very Low
Calorie Diet Reveals Potential Disease
State and Intervention Specific Biomarkers
Maria A. Sleddering1*., Albert J. Markvoort3., Harish K. Dharuri2, Skhandhan
Jeyakar3, Marieke Snel1, Peter Juhasz4, Moira Lynch4, Wade Hines4, Xiaohong
Li4, Ingrid M. Jazet1, Aram Adourian4, Peter A. J. Hilbers3, Johannes W. A. Smit1,
Ko Willems Van Dijk1,2
1. Departments of General Internal Medicine and Endocrinology & Metabolism, Leiden University Medical
Center, Leiden, The Netherlands, 2. Human Genetics, Leiden University Medical Center, Leiden, The
Netherlands, 3. Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The
Netherlands, 4. BG Medicine Inc., Waltham, Massachusetts, United States of America
*m.a.sleddering@lumc.nl
. These authors contributed equally to this work.
Abstract
Very low calorie diets (VLCD) with and without exercise programs lead to major
metabolic improvements in obese type 2 diabetes patients. The mechanisms
underlying these improvements have so far not been elucidated fully. To further
investigate the mechanisms of a VLCD with or without exercise and to uncover
possible biomarkers associated with these interventions, blood samples were
collected from 27 obese type 2 diabetes patients before and after a 16-week VLCD
(Modifast ,450 kcal/day). Thirteen of these patients followed an exercise program
in addition to the VCLD. Plasma was obtained from 27 lean and 27 obese controls
as well. Proteomic analysis was performed using mass spectrometry (MS) and
targeted multiple reaction monitoring (MRM) and a large scale isobaric tags for
relative and absolute quantitation (iTRAQ) approach. After the 16-week VLCD,
there was a significant decrease in body weight and HbA1c in all patients, without
differences between the two intervention groups. Targeted MRM analysis revealed
differences in several proteins, which could be divided in diabetes-associated
(fibrinogen, transthyretin), obesity-associated (complement C3), and diet-
associated markers (apolipoproteins, especially apolipoprotein A-IV). To further
investigate the effects of exercise, large scale iTRAQ analysis was performed.
However, no proteins were found showing an exercise effect. Thus, in this study,
specific proteins were found to be differentially expressed in type 2 diabetes
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Introduction
The incidence of insulin resistant states, such as the metabolic syndrome and type
2 diabetes (T2DM), has increased dramatically in recent years [1, 2]. T2DM is a
chronic multifactorial disease characterized by insulin resistance of the liver,
skeletal muscle and adipose tissue and the progressive failure of pancreatic b-cells
[3, 4]. Furthermore, research has shown that T2DM is associated with
inflammation, oxidative stress and vascular dysfunction [3, 5].
Over 80% of T2DM patients is overweight or obese [6, 7], nevertheless T2DM
develops in only about one-third of obese, insulin-resistant individuals.
Simultaneously, some 30% of obese (BMI.30) individuals seem metabolically
healthy. Whether these patients are protected from, or merely have a delayed risk
for developing T2DM is not known [8, 9]. Because of the contribution of obesity
to insulin resistance, it is essential for obese T2DM patients to reduce body
weight. The most fundamental aspect of the treatment of obesity is life-style
change, i.e. reduction of caloric intake and increase of physical activity. Very low
calorie diets (VLCD) have been shown to lead to a substantial amount of weight
loss and subsequently result in major metabolic improvements in obese T2DM
patients [10]. Recently, we have shown that a 16-week VLCD in T2DM patients
leads to a decrease in pericardial fat volume and an increase in quality of life
(QoL) [11, 12]. In addition, adding an exercise program to the VLCD in these
patients has been shown to have moderate additional favorable effects [13].
In the past decade large scale proteome analysis, also referred to as ‘proteomics’,
has been used to identify new biomarkers for the risk prediction of various
diseases, such as cancer, Alzheimer’s disease, cardiovascular disease and diabetes.
Proteomics can also be used to further elucidate disease mechanism and
molecular processes and to investigate the response of the body to interventions
[14, 15]. In diabetes research, proteomics have been analysed in various bodily
fluids, cell-lines and tissues, such as blood, urine, saliva, semen, vitreous fluid, b-
cells, adipocytes, hepatocytes and skeletal muscle [16–22]. However, most of the
proteomics studies are cross-sectional and there are currently no studies on
proteomic analysis in obese T2DM patients before and after a diet, the hallmark of
their treatment.
To gain more insight into the pathophysiology of type 2 diabetes we performed
plasma proteomics on the obese T2DM patients, before and after a VLCD with or
without exercise, for which clinical and metabolic improvements after the VLCD
were published before. [11–13, 23–25] Furthermore, we compared these T2DM
patients before and after the diet with obese and lean controls. Because of the
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patients versus controls and before and after a VLCD. These proteins are potential
disease state and intervention specific biomarkers.
Trial Registration: Controlled-Trials.com ISRCTN76920690
drastic weight loss and major improvements in glycemic control after such a diet,
we hypothesized that differences in proteins can be found that might be involved
in the development of, and recovery from, T2DM. By comparing the patients to
controls, we aim to uncover proteins differentially expressed in T2DM patients as
compared to lean and obese controls, and changes in these differences after the
intervention. In addition, by comparing the groups with and without exercise, we
aim to uncover possible biomarkers associated with the additional favorable
effects of adding an exercise program to the VLCD. Firstly, we conducted a
targeted MRM analysis of 13 abundant proteins hypothesized to be associated
with T2DM and obesity, including apolipoproteins and markers of inflammation
and coagulation. Subsequently, we performed a large scale iTRAQ analysis in
samples of the T2DM patients before and after the diet to uncover differences
between the VLCD with and without exercise groups also for less abundant
proteins.
Materials and Methods
Patients
The protocol of this study has been described previously [13]. In short, twenty-
seven (14 men, 13 women) T2DM patients were included in the study (Figure 1).
Diabetes duration was 8.9¡0.8 years (mean¡SEM) and patients were obese with
an average BMI of 37.2¡0.9 kg/m2. All patients were on insulin therapy (average
insulin dose 82¡11 units/day) with or without additional oral glucose-lowering
medication. Smoking, recent weight change (past 3 months), a history of
cardiovascular disease or any other chronic disease were reasons for exclusion.
Two control subjects were recruited via advertisements for every T2DM patient,
one lean and one obese subject. Control subjects were matched for gender, age,
race and geographical area. In addition, obese control subjects were matched for
BMI as well. Clinical characteristics are shown in Table 1.
Ethics statement
This study was conducted in accordance with the Declaration of Helsinki. The
study protocol was approved by the local ethics committee (Commissie Medische
Ethiek, Leiden University Medical Center) and written informed consent was
obtained from all subjects. The study was registered under ISRCTN76920690
(http://www.controlled-trials.com/isrctn/). The study was conducted between
2006 and 2009. The proteomics analysis was performed in 2010–2011. The
proteomic analysis was not planned when the study was approved by the ethics
committee, but was added later. The proteomics protocol is described in detail below.
Study design
All T2DM patients followed a VLCD for a period of 16 weeks. We randomly
assigned 13 of the 27 patients to simultaneously follow an exercise program. All
Proteomics in Type 2 DM Patients after a VLCD
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patients were provided with the same instruction forms and were all willing to be
randomized to either intervention. We then assigned the first 13 fit candidates to
the VLCD with exercise intervention. The following fit candidates were assigned
to the VLCD-only intervention. The patients were not aware of the randomization
order. Patients were studied before and after the VLCD intervention. Oral
glucose-lowering medication was discontinued three weeks before the start of the
Figure 1. Participant flowchart.
doi:10.1371/journal.pone.0112835.g001
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study and insulin therapy was stopped the day before. During the 16-week
intervention period, all glucose-lowering medication, including insulin, remained
discontinued.
VLCD
The VLCD consisted of three sachets of Modifast (Nutrition & Sante´, Antwerp,
Belgium), containing a total of 450 kcal per day. It provides about 50 to 60 grams
of carbohydrate, 50 grams of protein, 7 to 9 grams of lipid, 10 grams of dietary
fibers and all necessary vitamins and micronutrients. During the whole
intervention period, patients visited the outpatient clinic weekly for measurement
of body weight, to check glucoregulation and to confirm compliance with the diet.
Exercise program
Thirteen of the 27 T2DM patients simultaneously participated in an exercise
program. This program comprised a minimum of 4 days training at home for
30 min at 70% of maximum aerobic capacity on a cyclo-ergometer. Furthermore,
patients participated in a weekly one-hour aerobic exercise training under
supervision of a physiotherapist. Compliance was assessed by reading the heart
rate monitor worn during exercise sessions both at home and in the hospital
(Polar S610 i
tm, Polar Electro Oy, Finland). Patients in the VLCD-only group were
instructed to maintain their normal pattern of physical activity during the study.
Anthropometric and laboratory measurements
At baseline and after the 16-week intervention period patients were studied after
an overnight fast and after 2 days without any exercise. All T2DM patients
completed the 16-week VLCD and no patients were lost to follow-up. The lean
and obese control subjects were studied only once.
Height, weight, BMI and waist circumference were measured according to the
World Health Organization recommendations. Blood pressure was measured with
an Omron 705IT blood pressure device (Omron Matsusaka Co., Ltd., Japan) and
recorded within the limits of 1 mmHg. Fat mass was assessed by bioelectrical
impedance analysis (BIA, Bodystat 1500 MDD, Bodystat Ltd., Douglas, Isle of
Man, United Kingdom). Blood samples were drawn for the measurement of
fasting plasma levels of glucose, insulin, hemoglobin A1c (HbA1c), total
cholesterol (TC), high density lipoprotein (HDL)-cholesterol, low density
lipoprotein (LDL)-cholesterol and triglycerides (TG).
Proteomics measurements
Targeted protein assays through multiple reaction monitoring (MRM)
Ten mL of plasma aliquots were processed in 1.5-mL screw cap tubes. One
hundred ninety five mL of 100 mM TEAB/2M urea/10% acetonitrile/1% n-octyl-
glucoside/10 mM TCEP was added to the plasma samples. Samples were
Proteomics in Type 2 DM Patients after a VLCD
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incubated at room temperature for one hour for complete reduction. Four mL of
0.5 M iodoacetamide (Sigma-Aldrich) was added and alkylation was completed
for 30 minutes at room temperature. Forty mL of each aliquot of reduced/alkylated
plasma sample was digested with 12 mg sequencing grade trypsin. Digestion was
stopped after overnight incubation at room temperature by adding 45 mL of 2 M
urea/1% formic acid. To monitor LC/MS instrument trending, 0.3 mg
fibrinopeptide A standard (AnaSpec, Fremont, CA) was spiked into each sample
vial. Twenty mL of digested samples were injected for quantitative analysis.
LC-MRM analysis was performed on 4000QTrap instrument (AB/SCIEX,
Concord, ON) interfaced with a U3000 HPLC system (Dionex, Sunnyvale, CA).
Peptides were separated on a Targa C18 (5 mm) 15061.0 mm column (Higgins
Analytical, Mountain View, CA) utilizing a 200-mL/min flow rate. Peptides were
eluted carried out over a 21-min gradient from 2% B to 32%B (A: 5% acetonitrile,
0.1% formic acid, B: 95% acetonitrile, 0.1% formic acid). The HPLC column
compartment was kept at 50 C˚ during analysis.
Two peptides and two fragments from each were carefully selected to represent
the target proteins to be assayed. Thirteen target proteins were analyzed:
apolipoproteins A-I, A-IV, B100, C-III, E, Beta-2-glycoprotein 1 alpha-I-
antitrypsin, complement C3, fibrinogen alpha, beta, gamma chains, alpha-1-acid
glycoprotein and transthyretin. Accession numbers of these proteins are given in
Table 2, while Table S2 in File S1 shows the used peptide sequences.
Specimens from all T2DM and control subjects (114 samples) were analyzed in
three acquisition batches. Primary samples (following every four) were interleaved
with QC reference samples. MRM signals (ion intensities of fragments) from the
primary samples were normalized to the median signal from the same fragments
in the QC samples. This accurate relative quantification could be achieved without
the need of using isotope labeled peptide standards. MRM signals were integrated
using the Multiquant v1.1 software tool (AB/SCIEX).
iTRAQ Discovery Proteomics
Proteomic analysis was carried out by utilizing the 8-plex iTRAQ reagent for
relative quantification [26]. In this workflow a single 2D LC-MS/MS experiment is
used for the quantification of peptides (and proteins) from up to eight samples.
Eight-plex experiments were configured to profile six primary samples and two
replicates of reference (QC) sample that was created by combining a fraction of
the primary samples. By normalizing peptide measurements from the primary
samples to those in the QC samples it is feasible to compare large numbers of
primary samples analyzed in different experiments. The study - 54 primary
samples, 18 reference QC samples - consisted of nine such iTRAQ experiments.
One hundred mL plasma samples were delipidated by diluting with 400 mL
1XPBS (Sigma-Aldrich, St. Louis, MO) and 250 mL tetrachloroethylene (Sigma-
Aldrich), vortexing thoroughly and spinning at 14,000 rpm for 10 minutes at 4 C˚.
The resulting top aqueous phase was transferred to a new tube for further processing.
Abundant proteins were removed from delipidated plasma in two stages
utilizing IgY14 5-mL and Supermix 2-mL columns (Sigma) on a Vision HPLC
Proteomics in Type 2 DM Patients after a VLCD
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Workstation (Applied Biosystems, Foster City, CA) as described earlier [27]. The
protein fraction corresponding to the depletion flow-through was recovered on a
Poros R1 reversed-phase column, eluted with 95% acetonitrile and dried down in
a SpeedVac. Only this fraction was used for discovery proteomics. Dried protein
fractions were re-suspended in 22 mL 2 M urea, 1 M TEAB, 1% n-octyl-glucoside
buffer (pH 8.5) and reduced with 5 mM TCEP for one hour at room temperature.
Reduced samples were alkylated by adding 1 mL 84 mM iodoacetamide and
incubating in the dark for 30 minutes at room temperature. Trypsin digestion was
completed overnight at a 1:10 enzyme/substrate ratio (w/w) at room temperature
by adding 5 mL 1 mg/mL sequencing grade trypsin (Promega, Madison, WI) in
4 mM N-acetyl cysteine (to quench remaining iodoacetamide). Digested samples
were labeled by the 8-plex iTRAQ reagents following the manufacturer’s protocols
(Applied Biosystems) using an amount of digest pool containing approximately
40 mg material. Primary samples were labeled with the reagents yielding the m/z
114, 115, 116, 118, 119, 121 reporter fragments in the MS/MS scans. QC samples
(replicates from the reference pool) were labeled with the 113 and 117 reagents.
iTRAQ labeling was quenched by the addition of 1 M ammonium bicarbonate.
Eight samples were combined to an iTRAQ mix, desalted, and fractionated by
strong cation exchange (SCX) chromatography using a Poly Sulfoethyl Strong
Table 2. VLCD effect for proteins in the MRM dataset as compared to obese and lean controls.
T2DM controls
Protein description (Accession
number) baseline 16 weeks obese lean
Alpha-1-acid glycoprotein 1 (P02763) 1.02 ¡ 0.08 0.91 ¡ 0.05 1.06 ¡ 0.07 0.84 ¡ 0.06
Alpha-1-Antitrypsin (P01009) 1.01 ¡ 0.03 1.11 ¡ 0.04 #*{ 0.95 ¡ 0.05 0.97 ¡ 0.04
Apolipoprotein A-I (P02647) 0.95 ¡ 0.03 * 0.88 ¡ 0.04 *{ 1.03 ¡ 0.05 1.17 ¡ 0.06
Apolipoprotein A-IV (P06727) 1.33 ¡ 0.08 *{ 0.71 ¡ 0.06 #*{ 1.04 ¡ 0.06 1.06 ¡ 0.06
Apolipoprotein B-100 (P04114) 1.20 ¡ 0.07 *{ 1.00 ¡ 0.05 # 0.98 ¡ 0.04 0.92 ¡ 0.04
Apolipoprotein C-III (P02656) 1.36 ¡ 0.14 * 0.85 ¡ 0.05 # 1.02 ¡ 0.07 0.87 ¡ 0.06
Apolipoprotein E 1.24 ¡ 0.10 * 0.96 ¡ 0.05 # 1.01 ¡ 0.04 0.88 ¡ 0.05
(P02649)
Beta-2-glycoprotein 1 (P02749) 1.10 ¡ 0.03 *{ 1.02 ¡ 0.04 0.97 ¡ 0.05 0.94 ¡ 0.04
Complement C3 1.17 ¡ 0.03 * 0.97 ¡ 0.04 #* 1.08 ¡ 0.04 * 0.85 ¡ 0.04
(P01024)
Fibrinogen alpha chain (P02671) 1.04 ¡ 0.05 *{ 1.08 ¡ 0.05 *{ 0.87 ¡ 0.05 0.79 ¡ 0.09
Fibrinogen beta chain (P02675) 1.06 ¡ 0.04 *{ 1.12 ¡ 0.05 *{ 0.91 ¡ 0.05 0.82 ¡ 0.07
Fibrinogen gamma chain (P02679) 1.06 ¡ 0.04 *{ 1.13 ¡ 0.05 *{ 0.89 ¡ 0.04 0.82 ¡ 0.07
Transthyretin 0.87 ¡ 0.04 *{ 0.85 ¡ 0.04 *{ 1.07 ¡ 0.06 1.04 ¡ 0.04
(P02766)
The numerical entries represent ratio measurements relative to a pooled reference sample.
Mean ¡ SEM.
#significant difference within group vs. baseline;
*significant difference vs. lean controls;
{significant difference vs. obese controls.
doi:10.1371/journal.pone.0112835.t002
Proteomics in Type 2 DM Patients after a VLCD
PLOS ONE | DOI:10.1371/journal.pone.0112835 November 21, 2014 8 / 21
Cation Exchange Column (PolyLC, Columbia, MD) on an Agilent 1200
instrument (Agilent, Santa Clara, CA). Peptides were collected into nine SCX
fractions through eluting with a gradient of 10 mM KH2PO4 to 10 mM KH2PO4/
1M KCl at pH 3.5. SCX fractions dried and re-suspended in 50 mL 95:5:0.1 water-
acetonitrile-trifluoroacetic acid (TFA) (Buffer A for HPLC). Reversed-phase
separation was performed on a Dionex U3000 HPLC (Dionex, Sunnyvale, CA)
with a 60-min gradient from 5% solvent B (10% H2O/90% ACN/0.1% TFA) to
38% B. Eleven-second HPLC fractions were collected onto MALDI plates through
a Probot fraction collector (Dionex). MALDI matrix and mass calibration
standard were co-infused with a syringe pump at 2-ml/min flow rate. MALDI
plates were analyzed on an AB4800 mass spectrometer (Applied Biosystems/MDS
SCIEX, Concord, ON, Canada) utilizing internally developed scripts for MS/MS
precursor selection that was optimized to select and measure a reproducible set of
peptides from each iTRAQ mix.
Peptide quantification was carried out by calculating the average iTRAQ ion
intensity ratios relative to the m/z 113 and 117 peaks. Protein ratios were
determined as the medians of all peptide ratios matching to the same protein.
Peptide mappings are shown in Table S5 in File S1. Peptide sequences were
identified from MS/MS fragmentation spectra using the Mascot search engine
(Matrix Science, UK) the IPI sequence database (v3.72 of human sequences). For
peptide matching trypsin specificity was used with up to two missed cleavage sites.
iTRAQ modification, cysteine-alkylation, methionine oxidation, asparagine
deamidation, and N-terminal pyro-Gly and pyro-cmc formation were considered
as variable modifications. Precursor ion mass tolerance was 50 ppm and fragment
ion tolerance was 0.4 Da. Peptide matches were validated by an internally
developed procedure with an estimated rate of false peptide identification of less
than 1%, as explained by Juhasz et al [27]. Once all the study samples were
analyzed, the complete set of identified peptides was re-mapped to a minimum,
non-redundant protein set through an internally developed procedure. During
this process proteins that had unique peptides matching to them were kept
separate from protein groups that shared peptides. Measured values of protein
expression were normalized using a procedure based on Vandesompele et al [28].
Assays
Plasma glucose, TC, HDL-cholesterol and TG concentrations were analyzed as
previously described [13] with a fully automated P-800 module (Roche, Almere,
The Netherlands). Serum insulin was measured with an immunoradiometric assay
(Biosource, Nivelles, Belgium). HbA1c was detected with a semi automated HPLC
machine Primus Ultra 2 (Kordia, Leiden, The Netherlands).
Statistics
The data of the two intervention groups, i.e., both the clinical data and protein
expression levels measured from the MRM as well as iTRAQ platforms, were
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studied using a linear mixed effect model for repeated measures in order to study
the influence of the VLCD and the additional exercise program. The model was
fitted by Maximum Likelihood (ML). The initial model included the random
patient effects to account for the correlation between 2 repeated measures within
the same patient, and age, gender, treatment and time as fixed effects, for each
outcome variable separately. The model was tested for significance of each
individual factor and the interaction effect of time and treatment. On doing so, it
was found that the effects of age and gender were not significant. The final model
consisted of the random patient effects, the fixed treatment and time effects, and
the interaction between treatment and time. The influence of the VLCD was tested
by studying the effect of time on the model and the additional influence of
exercise with VLCD was tested by studying the effect of treatment and time
interaction on the model. The p values for each of the tests are reported.
Differences between all groups in the clinical dataset as well as in the MRM
dataset, i.e., two intervention groups and the lean and obese control groups, were
analysed using t-tests, where paired t-tests were used when comparing two time
points for the same group and independent t-tests for all other comparisons.
Adjustment for multiple hypothesis testing has been performed in all proteomics
analyses using the Benjamini-Hochberg (BH) method (unless otherwise stated in
the text). A significance level of p50.05 was used (unless otherwise stated in the
text). Data are presented as mean¡SEM. The statistical analyses were conducted
using the free software R version 2.10.1 with the lme4 and multcomp libraries
[29–31].
Results
Effect on body weight and glucoregulation
Anthropometric and laboratory results were published previously. [11–13, 23–25]
As shown in Table 1, there were no significant differences in clinical
characteristics, except for systolic blood pressure, between the VLCD+exercise and
the VLCD-only group at baseline. Furthermore, the control groups were well
matched with both intervention groups with respect to age and gender and for the
obese control group with both intervention groups at baseline with respect to
weight, BMI and waist circumference. Both control groups had significantly lower
levels of glucose, insulin and HbA1c.
After the 16-week VLCD there was a significant decrease in body weight in both
intervention groups (227.2¡1.9 kg VLCD+exercise; 223.7¡1.6 kg VLCD-
only). Patients also lost a significant amount of fat mass and waist circumference.
Moreover, the 16-week VLCD resulted in an impressive improvement in
glycaemic control as shown by a significant decrease in HbA1c in both treatment
groups (VLCD + exercise 7.8¡0.4 vs. 6.3¡0.4%; VLCD-only 7.8¡0.3 vs.
6.7¡0.3%), despite the discontinuation of all glucose-lowering medication. In
both treatment groups, plasma TG were significantly decreased to near normal
values. After the 16-week intervention period the VLCD+exercise group had
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significantly less fat mass and a significantly lower total cholesterol level as
compared to the VLCD-only group. There was no significant difference in
glucoregulation between the groups after the 16-week intervention period
(Table 1).
Targeted MRM analysis
A total of 15 proteins, including 2 internal control proteins (not shown), were
quantified using MRM and mass spectrometry in the VLCD groups, with and
without exercise and before and after the intervention. These proteins were also
quantified in the obese and lean controls.
Intervention effects
After 16 weeks, there was a significant decrease in concentrations of
apolipoproteins A-IV, B-100, C-III and E as well as of Complement C3 in both
intervention groups. These effects were however not significantly different
between the two intervention groups (see Table S1 in File S1). Since no additional
influence of exercise with VLCD was observed for any of the proteins in the MRM
set, the VLCD+exercise and VLCD-only groups were combined for further
analysis into one group of T2DM patients. Table 2 shows the full comparison of
the combined T2DM group at the two time points (T2DM0 and T2DM16,
respectively) with the two control groups (lean and obese).
Apolipoprotein A-IV showed the most significant effect of VLCD among all
proteins considered in the MRM dataset. Apolipoprotein A-IV concentration did
not differ between both control groups (lean 1.06¡0.06 vs. obese 1.04¡0.06
A.U., p50.90), however, the level for T2DM patients was significantly higher
(1.33¡0.08 A.U.) compared to both control groups (p50.01 for lean and p50.04
for obese) before the diet, whereas the level for T2DM patients was significantly
lower to those of the controls (p50.002 for lean and p50.003 for obese) after the
diet.
Also for apolipoproteins E, C-III and B-100 the concentration levels were
significantly higher for T2DM patients at baseline compared to the lean control
group, and VLCD resulted in significant decrease in their concentration levels.
Contrary to Apolipoprotein A-IV, these decreased levels after the diet are not
significantly different from the control groups.
Obesity associated markers - Only Complement C3 showed a significant
difference between the lean control group and all three other groups. These
differences were highly significant for lean against obese (0.85¡0.04 vs 1.08¡0.04
A.U., p50.001) as well as for lean against the T2DM group at baseline (0.85¡0.04
vs 1.17¡0.03 A.U., p,0.001). Upon the VLCD, the concentrations of C3
decreased (from 1.17¡0.03 to 0.97¡0.04 A.U., p,0.001), and, although still
significantly different (p50.04), approached the concentration in the lean control
group.
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Disease state discriminating proteins
Diabetes associated markers - The fibrinogens alpha, beta and gamma chains
all showed the same behaviour. Namely, all three showed a significantly increased
level for T2DM patients as compared to both the lean and the obese controls, both
at baseline and after 16 weeks of VLCD, although these increased levels for T2DM
patients at baseline as compared to the obese were only just significant (p50.04
for all three). Moreover, all three showed no significant difference between obese
and lean (p50.58 for all three) nor between the T2DM patients before and after
the diet (p>0.12).
Transthyretin showed a very similar behaviour as the fibrinogens except for the
fact that the transthyretin level was lower for T2DM patients as compared to the
controls.
Large scale iTRAQ analysis
A total of 635 proteins were quantified using iTRAQ and mass spectrometry in the
VLCD groups, with and without exercise and before and after the intervention.
Only 234 of those proteins could be measured for all 27 patients on both time-
points (i.e., at baseline and after the 16-week VLCD). These included two proteins
added as internal controls. The data analysis was applied on the remaining 232
proteins.
Exercise associated markers
Of the 232 proteins 18 showed a significant exercise effect when considering the
unadjusted p-value measured by the interaction of treatment and time from the
model (see Table S3 in File S1). Amongst these, for two proteins SHBG and
MASP-1, the p-value was lower than 0.005. For SHBG, the mean of the
measurements for VLCD+exercise at 16 weeks showed a stronger increase from
the measurements at baseline (VLCD+exercise at 16 weeks: 1.32¡0.16 A.U. vs
VLCD+exercise at baseline: 0.69¡0.09 A.U.) in comparison to the increase for
VLCD-only (VLCD-only at 16 weeks: 1.04¡0.08 A.U. vs VLCD-only at baseline:
0.74¡0.05 A.U.). For MASP-1, the level for the VLCD+exercise group was
decreased after 16 weeks (VLCD+exercise at 16 weeks: 0.86¡0.04 A.U. vs
VLCD+exercise at baseline: 0.99¡0.03 A.U.) whereas the level for the VLCD-only
group hardly changed (VLCD at 16 weeks: 0.93¡0.02 A.U. vs VLCD at baseline:
0.92¡0.03 A.U.). However, on applying the multiple testing correction, none of
the analytes were found to be significant.
VLCD associated markers
Of the 232 proteins, 87 showed a significant VLCD effect, where the effect is
considered to be statistically significant if the unadjusted p-value from the model
for the effect of time was less than 0.05 and the Benjamini-Hochberg-adjusted p-
value was less than 0.10. Fourtysix proteins from these significant cases were up-
regulated after treatment, i.e., the measured expression levels were higher after 16
weeks of VLCD than at baseline, while the other 41 proteins were down-regulated
after 16 weeks of VLCD. The top 13 proteins (based on p-value) identified from
Proteomics in Type 2 DM Patients after a VLCD
PLOS ONE | DOI:10.1371/journal.pone.0112835 November 21, 2014 12 / 21
iTRAQ experiments showing a VLCD effect are shown in Table 3. A list of all
proteins and their changes after 16 weeks of VLCD are shown in Table S4 in File
S1. Fourtyfour of the significantly changed proteins could be traced to pathways
in KEGG, with 17 of them being present in the Complement and Coagulation
cascade.
Discussion
Using a targeted MRM analysis we showed that several proteins differ between
T2DM patients before and after a VLCD and between T2DM patients and lean
and obese controls. As shown in Figure 2, these proteins can be divided in
subgroups based on similar patterns of differences between the groups. Thereby a
distinction can be made between potential biomarkers that are intervention (diet)
or disease state (diabetes or obesity) associated.
Diet associated markers
The proteins showing a diet effect most evidently in this study were the
apolipoproteins, especially apolipoprotein A-IV (APOA-IV), as shown in
Figure 2. APOA-IV is synthesized by the enterocytes of the small intestine in
response to fat absorption [32, 33]. Although the precise role of APOA-IV has not
been fully elucidated, studies suggest that it has anti-atherogenic [34] and anti-
inflammatory [35] properties and that it serves as a satiety factor [32, 36].
Interestingly, APOA-IV levels were significantly higher in T2DM patients before
the diet as compared to controls, which was also found in earlier studies [37, 38].
Table 3. Top 13 proteins identified from iTRAQ experiments showing a VLCD effect.
T2DM
Protein description (Accession number; number of peptides quantified) Baseline 16 weeks adj. p-value
Biotinidase (P43251; 13) 0.96 ¡ 0.02 0.86 ¡ 0.02 6.0E-07
Selenoprotein P (P49908; 7) 0.80 ¡ 0.02 0.95 ¡ 0.02 1.0E-06
Insulin-like growth factor-binding protein 2 (P18065; 6) 0.68 ¡ 0.04 1.04 ¡ 0.06 1.0E-06
Inter-alpha-trypsin inhibitor heavy chain H4 (Q14624; 41) 0.79 ¡ 0.02 0.97 ¡ 0.02 1.0E-06
Sex hormone-binding globulin (P04278; 11) 0.72 ¡ 0.05 1.18 ¡ 0.09 1.7E-06
Interleukin-1 receptor accessory protein (Q9NPH3; 7) 0.75 ¡ 0.02 0.88 ¡ 0.03 2.0E-06
Afamin precursor (P43652; 40) 0.95 ¡ 0.04 0.78 ¡ 0.03 2.6E-05
Apolipoprotein A-IV precursor (P06727; 31) 1.23 ¡ 0.09 0.78 ¡ 0.06 2.6E-05
Leucine-rich alpha-2-glycoprotein (P02750; 18) 0.72 ¡ 0.02 0.92 ¡ 0.04 2.7E-05
Beta-Ala-His dipeptidase (Q96KN2; 19) 1.12 ¡ 0.05 0.91 ¡ 0.03 3.4E-05
Lysozyme C (P61626; 5) 0.81 ¡ 0.04 0.92 ¡ 0.04 6.6E-05
Pigment epithelium-derived factor (P36955; 17) 1.22 ¡ 0.05 0.95 ¡ 0.04 6.8E-05
Fructose-bisphosphate aldolase B (P05062; 6) 1.05 ¡ 0.06 0.80 ¡ 0.03 2.5E-04
The numerical entries represent ratio measurements relative to a pooled reference sample.
Mean ¡SEM.
doi:10.1371/journal.pone.0112835.t003
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In contrast to our study, some also showed higher APOA-IV levels in obese, non-
diabetic mice and humans [39, 40], though others did not find an association
between APOA-IV and BMI [41]. An explanation for the higher APOA-IV levels,
which is counter-intuitive, has not yet been identified. Shen et al. showed that
obese mice, although peripheral APOA-IV levels were high, have lower APOA-IV
levels in the hypothalamus, the site where APOA-IV is thought to exert its effect
on satiety [39]. It has also been hypothesized that the high APOA-IV levels reflect
a state of APOA-IV resistance [42], as is the case for leptin, which is also been
thought to regulate APOA-IV [39].
Figure 2. Graph representation of group wise comparisons for the proteins in the MRM data set.
Comparisons between all pairs of the four groups, i.e., the diabetes patients at baseline (T2DM0) and after 16
weeks of VLCD (T2DM16) as well as the obese and lean control groups, are represented by edges, where the
thickness of the edge represents the p-value. Groups that hardly can be discerned are thus connected by
thick edges and located close together, whereas groups that can be well distinguished are connected by thin
edges and are slightly further distinct. Furthermore, the proteins have been clustered into groups (i.e., obesity
associated, diabetes associated, diet associated, and non- associated) based on similarity in patterns of
differences between the groups.
doi:10.1371/journal.pone.0112835.g002
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APOA-IV also showed the highest MFC in response to the VLCD, resulting in
significantly lower APOA-IV levels in T2DM patients after the diet than in
controls. This decrease was consistently shown in 100% of the subjects, indicating
that a decrease in APOA-IV might be a marker for weight loss. On the other hand
it is known that APOA-IV levels are influenced by changes in dietary fat content
[40, 43] and the observed decrease might thus be more reflective of the low
amount of fat intake and caloric restriction during the VLCD. It would be
interesting to investigate APOA-IV levels in patients back in a eucaloric state to
elucidate this further. Furthermore, it has been hypothesized that, as APOA-IV
serves as a satiety factor, lower APOA-IV levels can be a signal for stimulating
feeding behavior [44]. Low APOA-IV levels may therefore contribute to the
difficulties in maintaining achieved weight loss over longer periods of time. In this
context it is interesting that in a study by Culnan et al., using iTRAQ proteomic
analysis, an increase in APOA-IV levels was shown after weight loss induced by
Roux-en-Y gastric bypass surgery (RYGB), which is known to result in more
sustained weight loss as compared to diets [42]. The contrasting APOA-IV levels
may, however, be explained by the fact that those after-surgery levels were
measured after a mean follow-up of 19.2 months post-RYGB, and by the altered
anatomy of the small intestine, the production site of APOA-IV.
Complement C3 - an obesity associated marker
Accumulating evidence shows that both T2DM and obesity are associated with a
chronic inflammatory state [3]. Complement C3 (C3) has an important role in
the immune system and is produced by the liver, adipose tissue and macrophages
[45]. Our MRM analysis showed higher concentrations of C3 in obese T2DM
patients and healthy obese subjects as compared to lean controls. This agrees with
several other studies, that also showed such elevated levels of C3 in patients with
obesity [45, 46]. Furthermore, a significant decrease in C3 levels was seen after the
VLCD, whereas no differences were shown between obese subjects with or without
T2DM, indicating that C3 might be a marker of obesity rather than T2DM.
However, other studies have demonstrated C3 levels to be increased in lean versus
obese T2DM patients and to be associated with diabetes development
independently of body weight [47, 48]. C3 has also proved to be higher in young
adults with type 1 diabetes and a decrease in HbA1c in this group has been
associated with a decrease in C3 levels [49]. These data indicate that C3 level and
changes therein are dependent on the pathophysiology of the patient.
Diabetes-associated markers
The fibrinogens were found to be elevated in T2DM patients as compared to both
lean controls and obese controls, before as well as after the diet. Furthermore,
concentrations did not differ between lean and obese controls, suggesting that
fibrinogen is more diabetes than obesity associated. A high fibrinogen level is
thought to reflect a hypercoagulable state and is suggested to be a strong
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independent cardiovascular risk factor [50, 51]. Other studies also found high
fibrinogen levels in T2DM patients [52, 53] and this may contribute to the
increased risk of cardiovascular events in type 2 diabetes [54, 55]. However, not all
studies showed an increased fibrinogen level in T2DM patients [56]. After the
VLCD we did not observe differences in the fibrinogen levels, although weight loss
has been associated with a decrease in fibrinogen in literature [57].
Another interesting diabetes-associated marker found in this study is
transthyrethin (TTR). TTR, previously known as pre-albumin, is a carrier protein
for thyroid hormones and retinol-binding protein and is produced in the liver,
choroid plexus and pancreatic islets [58]. TTR has been used as a biomarker for
malnutrition [59–61] and has been shown to decrease in response to a VLCD [62–
64]. However, it has been shown by Afolabi et al. that after an initial decrease at
5% weight loss, TTR levels returned back to baseline upon further weight loss
[65]. In our study, where the average weight loss is 22%, also no differences were
found after the VLCD.
Exercise effect
No significant exercise effect was observed for any of the proteins in the MRM
analysis. Therefore, we performed a large scale iTRAQ proteomic analysis to reveal
candidate pathways involved in the additional beneficial effects of adding an
exercise program that we have shown before [13]. Without correcting for multiple
testing, concentrations were significantly different between the two VLCD groups
for a few proteins, of which especially sex hormone-binding globulin (SHBG,
P04278) and mannose-binding lectin (MBL)-associated serine protease (MASP-1,
P48740) could be interesting. MASP-1 is a protease that contributes to the
activation of the lectin complement pathway [66]. SHBG has been related to
exercise before, although the influence of exercise on SHBG levels is less clear [67–
70]. Moreover, SHBG levels are known to be inversely associated with insulin
resistance and are thought to predict the risk on T2DM [71]. After correction for
multiple testing, however, none of the proteins showed significant differences
between the groups any more. Further research on these specific proteins is
needed to uncover possible pathways involved in the beneficial effects of exercise.
Strengths and limitations
The major strength of our study is the VLCD intervention. By studying T2DM
patients before and after the diet, we showed that several proteins change with
weight loss and improved glycemic control. By comparing the patients to obese
and lean controls, these proteins could further be discerned between diabetes-
associated and obesity-associated markers.
Limitations of our study are the lack of a control (non-diabetic obese) VLCD
group as well as the absence of lean and obese control groups in the iTRAQ
analysis. In addition, because of the many comparisons and the consequentially
required correction for multiple testing, no significant differences were found
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using the iTRAQ analysis. The study would benefit from quantification of one or
more promising candidates by an independent complementary technology (e.g.
ELISA). This was, however, beyond the scope of the current study.
In conclusion, using proteomic analysis several potential disease state and
intervention associated markers were found distinguishing T2DM patients from
obese and lean controls and showing a VLCD effect. Although no specific exercise
markers were discovered, the iTRAQ analysis indicated some proteins as potential
interesting targets for further research.
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